Diagnostic Value of HE4 in Distinguishing Malignant from Benign Pelvic Masses-Reference-Cited by-同舟云学术

Diagnostic Value of HE4 in Distinguishing Malignant from Benign Pelvic Masses

Published:2016-08-29 Issue:3 Volume:14 Page:
ISSN:2363-8397
Container-title:Indian Journal of Gynecologic Oncology
language:en
Short-container-title:Indian J Gynecol Oncolog

Author:

Onal Mesut,Malatyalioglu Erdal,Kurtoglu Ozdes Emel,Celik Handan,Yanik Keramettin,Tosun Migraci,Bildircin Fatma Devran,Alper Tayfun,Cetinkaya Mehmet Bilge,Kokcu Arif

Publisher

Springer Science and Business Media LLC

Subject

Obstetrics and Gynaecology,Oncology

Link

http://link.springer.com/content/pdf/10.1007/s40944-016-0079-8.pdf

Reference30 articles.

1. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136:359–86.

2. Yang Z, Luo Z, Zhao B, Zhang W, Zhang J, Li Z, et al. Diagnosis and preoperative predictive value of serum HE4 concentrations for optimal debulking in epithelial ovarian cancer. Oncol Lett. 2013;6:28–34.

3. Kristjansdottir B, Levan K, Partheen K, Sundfeldt K. Diagnostic performance of the biomarkers HE4 and CA125 in type I and type II epithelial ovarian cancer. Gynecol Oncol. 2013;131:52–8.

4. Jacobs I, Oram D, Fairbanks J, Turner J, Frost C, Grudzinskas JG. A risk of malignancy index incorporating CA 125, ultrasound and menopausal status for the accurate preoperative diagnosis of ovarian cancer. Br J Obstet Gynaecol. 1990;97:922–9.

5. Moore RG, McMeekin DS, Brown AK, DiSilvestro P, Miller MC, Allard WJ, et al. A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass. Gynecol Oncol. 2009;112:40–6.